Linda Huber uses her biochemistry background and patent experience to represent medical and academic institutions, private foundations and medical device and pharmaceutical companies in intellectual property matters.
I focus on prosecuting biotechnology and life sciences patents, counseling clients on their patent portfolios and prosecution strategies, conducting due diligence of patent portfolios in corporate transactions and patent license agreements and advising clients on patent related license provisions.
Particular areas I focus on include cancer therapeutics, gastrointestinal diseases, diagnostics, gene therapy, stem cells, inflammatory conditions, neurological diseases, and nutritional products.
Through my understanding of my clients’ needs and goals, I develop and implement strategies to strengthen, manage and expand their patent portfolios. I also help them understand the implications of licensing terms.
Even with the current jurisprudence on subject matter eligibility, I see that strong patent protection can still be achieved by covering the technology via different angles. Academic institutions and companies, having a strategic patent prosecution plan, should not be deterred from pursuing patent protection for their innovations.
Represented Cedars-Sinai Medical Center in prosecuting, licensing, and enforcing patent rights on methods of treating irritable bowel syndrome (“IBS”), a chronic condition affecting more than 15% of the general population. Cedars-Sinai doctors invented groundbreaking treatments for IBS, and the NP team helped Cedars-Sinai patent these discoveries and license them to Salix Pharmaceuticals, a wholly-owned subsidiary of Bausch Health Companies Inc. After Actavis Laboratories FL, Inc. sought FDA approval to market a generic competitor drug, NP represented Cedars-Sinai in litigation with its licensees against the infringing generic competitor. That litigation recently was resolved under confidential terms that assure Cedars-Sinai’s patent rights will be protected through their expiration.
Law360 | April 28, 2017
This article mentions recent leadership promotions at the firm including David Brown, Jared Lusk, Jim Vallee, Graham Beck, Kathleen Ceglarski Burns, Emily Crandall Harlan, Daniel Gibbons, Linda Huber, Ilana Kameros, Haydon Keitner, Darren Miller, Neal Pandozzi, Edward Puerta, Stephen Reil, and Elizabeth Young.
University of San Diego School of Law, J.D., cum laude
University of California, Los Angeles, B.S., Biochemistry
California
U.S. Patent and Trademark Office
